“Asia continues to play an increasingly important role in advancing innovation across the global biopharma industry,” said Dani...
New addition strengthens SK Biopharmaceuticals' radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partne...
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in Europe Omlyclo™ 300 mg/2ml prefilled syringe (PFS) p...
-Galux, a South Korean biotech pioneering AI-driven protein therapeutics design, announced new experimental findings demonstrating that its AI protein de...
LISCure Biosciences ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 cl...
Patent expands MEAI’s global intellectual property protection as Clearmind advances clinical development and commercialization plans Clearmind Med...
Samsung Bioepis will assume full commercial responsibility for BYOOVIZ®(ranibizumab) upon full transition of Biogen’s commercializa...
SK pharmteco, a global contract development and manufacturing organization (CDMO), announced today a $6.1 million investment in its Rancho Cordova facili...
Members of Management and Business Development will be at BioProcess International Asia in Kyoto, Japan, October 20-22, 2025 Company will introduce th...
Angelini Pharma, part of the privately owned Angelini Industries, and Sovargen, a South-Korean biotechnology company, announced today that they signed an...
Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applic...
-Celltrion Pharm , a South Korean biopharmaceutical firm, said on September 16 that it has inked a strategic trilateral agreement with a multination...
Samsung Biologics, South Korea’s preeminent contract development and manufacturing organisation (CDMO), has entered into a momentous W1.8 tri...
Secures third contract this year, reinforcing global competitiveness and expanding strategic partnerships LOTTE BIOLOGICS (CEO James Park) announce...
© 2025 Biopharma Boardroom. All Rights Reserved.
